Latest News and Press Releases

LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for...

LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...

Pune, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Global Bioelectronics Market [2023-2029] Research Report Analysis and Outlook Insights | Latest Updated Report | 106 Pages Report | The Bioelectronics Market...

LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...

LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...

LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...

Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...

LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...